Report Says BRIC Countries Must Be Dealt With Individually, Not As Group
This article was originally published in PharmAsia News
Executive Summary
Although global drug manufacturers may lump Brazil, Russia, India and China under the same BRIC rubric of emerging-market opportunities, each offers a special challenge as it deals with its health-care infrastructure.